# Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma

> **NCT00089193** · PHASE2 · COMPLETED · sponsor: **Craig L Slingluff, Jr**

## Conditions studied

- Melanoma (Skin)

## Interventions

- **BIOLOGICAL:** incomplete Freund's adjuvant
- **BIOLOGICAL:** multi-epitope melanoma peptide vaccine
- **BIOLOGICAL:** sargramostim

## Key facts

- **NCT ID:** NCT00089193
- **Lead sponsor:** Craig L Slingluff, Jr
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-09
- **Primary completion:** 2007-02
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2014-12-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00089193

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00089193, "Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00089193. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*